The US Justice Department is examining how Andreessen Horowitz arranges board seats and director control across its portfolio companies. The narrow legal hook is old but rarely enforced: Section 8 of the Clayton Act, which bars a person from sitting on the boards of competing firms.
The strategic significance is larger than one firm. Over the past decade, mega-funds turned board seats, observer rights, and information access into instruments of soft control across entire sectors. A single fund can hold governance leverage over multiple startups chasing the same market, shaping hiring, pricing, and who gets funded next. If the DOJ treats that pattern as an antitrust problem rather than routine venture practice, the entire post-2015 growth-capital model faces friction. Expect funds to preemptively swap voting seats for passive observer roles, tighten information walls between competing portfolio companies, and lean on outside independent directors. The immediate effect is not fewer deals but more cautious, more lawyered governance, and slower decision cycles inside boards that used to move on a partner's word.
For Japan, the timing is pointed. Corporate venture capital has become a core strategy for SoftBank, Sony, NTT, and the trading houses, alongside a wave of SIer and manufacturer venture arms taking board seats in domestic and US startups. Japanese CVCs often justify investments by strategic access rather than pure return, precisely the arrangement now under scrutiny. A firm holding directorships across rival AI or robotics startups could find its US-facing deals exposed to the same questions, and cross-shareholding culture makes Japanese players structurally prone to interlocking directorates.
SIers and enterprise IT leaders investing in startups to secure talent and technology should treat this as a governance signal. The practical move is to separate strategic partnership from board control: use commercial contracts and minority stakes without voting directorships in competing bets, and document information barriers. For Japanese funds raising or co-investing in the US, legal review of board structures is no longer optional hygiene.
The deeper shift is philosophical. Venture governance has long operated on trust and relationship density; regulators are beginning to read that density as concentration. Japanese firms building CVC muscle now should design for that scrutiny from the start rather than retrofit it later.
